SCNI — Scinai Immunotherapeutics Balance Sheet
0.000.00%
- $0.13m
- $15.02m
Annual balance sheet for Scinai Immunotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | 10-K | 20-F |
Standards: | IFRS | IFRS | IFRS | USG | USG |
Status: | fx Final | fx Final | fx Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 21 | 2.93 | 17.4 | 14.1 | 4.87 |
Net Total Receivables | 0.19 | 0.375 | 0.326 | — | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 21.2 | 3.31 | 17.7 | 14.4 | 5.45 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 12.2 | 14.3 | 14.2 | 12.7 | 12 |
Other Long Term Assets | |||||
Total Assets | 33.5 | 17.7 | 32.1 | 27.1 | 17.5 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 5.49 | 20 | 2.32 | 2.34 | 1.78 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 52.4 | 22.3 | 24.6 | 28.8 | 22 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -18.8 | -4.55 | 7.52 | -1.76 | -4.57 |
Total Liabilities & Shareholders' Equity | 33.5 | 17.7 | 32.1 | 27.1 | 17.5 |
Total Common Shares Outstanding |